Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company, announced on Monday that Ronald Hao Xi Ede will retire from his position as chief financial officer (CFO) after a seven-year distinguished career with the company, and it has named Fei You as its new CFO, effective 5 February 2024.
Ede will continue to serve on the board as an executive director, participating in the board's strategic and business decisions, as well as serving as the managing partner of the company's funds and take full charge of the company's fund management.
In her new role, You will be responsible for the company's financial management and capital market activities. You has more than 20 years of experience in financial management, strategic investment and financing. She has served as the chief financial officer of Jinxin Fertility Group Ltd. (HKEx stock code: 1951) and successfully headed its listing on the Main Board of the Hong Kong Stock Exchange. She has worked in various managerial positions with 3SBio Inc. (HKEx stock code: 1530) and KPMG.
Dr Michael Yu, Innovent Biologics founder, chairman and CEO, said, 'We are deeply grateful for the dedication and contribution Ronnie has made during his entire tenure at Innovent. His strategic judgment and leadership were instrumental in transforming Innovent from a biotech company to a biopharma enterprise, and leaves us in a solid position to continue pursuing our long-term global vision. We will continue to work with him on the board of the company and in other areas. At the same time, we warmly welcome Ms Fei You as our new CFO. Ms You has extensive expertise and experience in financial management and capital markets in the healthcare industry. We look forward to working with her on the journey toward pursuing our mission of 'developing high-quality biopharmaceuticals that are affordable to ordinary people' and our vision of 'being one of the world's leading biopharmaceutical companies.'
;;;
Innovent Announces Retirement of CFO and Appointment of New CFO USA - English
NEWS PROVIDED BY
Innovent Biologics 05 Feb, 2024, 03:41 ET
SHARE THIS ARTICLE
ROCKVILLE, Md. and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("c") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that Mr. Ronald Hao Xi Ede will retire from his position as the chief financial officer after a seven-year distinguished career with the Company. Mr. Ede will continue to serve on the Board as an executive director, participating in the Board's strategic and business decisions, as well as serve as the managing partner of the Company's funds and take full charge of the Company's fund management.
Mr. Ede joined Innovent in 2017 and, during his CFO tenure, has made significant contributions to the Company's strategy planning, corporate governance, financial management and business development. He successfully led the listing of the Company on the Main Board of the Hong Kong Stock Exchange and a series of post-listing fund raising activities, which have laid a solid foundation for Innovent's continuous growth.
At the same time, Innovent has appointed Ms. Fei You as the new CFO, effective February 5, 2024. She will be responsible for Innovent's financial management and capital market activities. Ms. You has over 20 years of experience in financial management, strategic investment and financing. Before joining Innovent, she served as the chief financial officer of Jinxin Fertility Group Ltd. (HKEx stock code: 1951) and successfully led its listing on the Main Board of the Hong Kong Stock Exchange. Prior to that, she had served in various managerial positions with 3SBio Inc. (HKEx stock code: 1530) and KPMG.
"We are deeply grateful for the dedication and contribution Ronnie has made during his entire tenure at Innovent. His strategic judgment and leadership were instrumental in transforming Innovent from a biotech company to a biopharma enterprise, and leaves us in a solid position to continue pursuing our long-term global vision. We will continue to work with him on the Board of the Company and in other areas, "said Dr. Michael Yu, Founder, Chairman and CEO of Innovent Biologics. "At the same time, we warmly welcome Ms. Fei You as our new CFO. Ms. You has extensive expertise and experience in financial management and capital markets in the healthcare industry. We look forward to working with her on the journey toward pursuing our mission of 'developing high-quality biopharmaceuticals that are affordable to ordinary people' and our vision of "being one of the world's leading biopharmaceutical companies.'"
About Innovent
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients' lives. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), SULINNO® (Adalimumab Injection), HALPRYZA® (Rituximab Injection), Pemazyre® (Pemigatinib Oral Inhibitor), olverembatinib, Cyramza® (Ramucirumab Injection), Retsevmo® (Selpercatinib Capsules ), FUCASO® (Equecabtagene Autoleucel Injection) and SINTBILO® (Tafolecimab Injection). Additionally, it has 2 NDA under NMPA review, 5 assets in Phase III or pivotal clinical trials, and 19 more molecules in early clinical stage.
Innovent has also entered into 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives.
Note:
TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT® (sintilimab injection, Innovent)
BYVASDA® (bevacizumab biosimilar injection, Innovent)
HALPRYZA® (rituximab biosimilar injection, Innovent)
SULINNO® (adalimumab biosimilar injection, Innovent)
Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.
CYRAMZA® (ramucirumab, Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.
Retsevmo® (selpercatinib, Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.
Disclaimer: Innovent does not recommend any off-label usage.
Innovent's Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
SOURCE Innovent Biologics
Source: https://www.prnewswire.com/news-releases/innovent-announces-retirement-of-cfo-and-appointment-of-new-cfo-302053090.html
;;;
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation